# EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

> **NCT04515043** · PHASE1 · COMPLETED · sponsor: **Invectys** · enrollment: 6 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.

## Key facts

- **NCT ID:** NCT04515043
- **Lead sponsor:** Invectys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2020-12-19
- **Final completion:** 2020-12-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515043, "EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04515043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*